Renal failure in cancer patients is not a rare clinical condition and often contraindicates anticancer drug treatment; moreover, chemotherapeutic drugs are frequently identified as possible iatrogenic cause of renal failure. Molecular therapies, when appropriate, could represent a therapeutic option for cancer patients with severe renal disease, but the lack of knowledge in this field, at present, limits their use in patients undergoing dialysis. Herein we describe a case, at our knowledge the first reported, of a patient with advanced lung adenocarcinoma on maintenance hemodialysis treated with gefitinib and then with afatinib; we also reviewed the literature on epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) used in NSCLC patients with concomitant renal impairment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Copper metabolism-related lncRNAs predict prognosis and immune landscape in liver cancer patients.
Transl Cancer Res
November 2024
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Background: Characterized by its high mortality and easy recurrence, hepatocellular carcinoma (HCC) poses significant clinical challenges. The association between copper metabolism and development of cancer has been identified. However, the underlying mechanisms of copper metabolism-related long non-coding RNAs (CMRLs) in HCC remain elusive.
View Article and Find Full Text PDFComprehensive analysis of the transcription factor CREB3L4/RASEF signaling axis in lung adenocarcinoma: implications for pathogenesis and therapeutic strategies.
Am J Transl Res
November 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University Kunming 650032, Yunnan, China.
Objectives: This study aims to elucidate the role of cAMP responsive element binding protein 3 like 4 (CREB3L4) in the pathogenesis of lung adenocarcinoma (LUAD) and to provide new insights and approaches for its effective treatment. An analysis was conducted on the expression and prognostic implications of CREB3L4 in LUAD.
Methods: Potential downstream target genes regulated by CREB3L4 were identified through chromatin immunoprecipitation assay sequencing and mRNA sequencing analyses, and the regulatory relationship, mechanism, and prognostic significance of the identified target gene in LUAD were subsequently confirmed.
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.
Thorac Cancer
December 2024
Department of Chemotherapy, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Introduction: First-line osimertinib is widely used to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancers (NSCLC). In clinical practice, rechallenge therapy with another EGFR-tyrosine kinase inhibitor (TKI) is often performed after first-line TKI discontinuation owing to resistance or toxicity; however, the efficacy and toxicity of EGFR-TKI rechallenge after first-line osimertinib have not been adequately investigated. This study aimed to examine the efficacy and safety of EGFR-TKI rechallenge with another TKI.
View Article and Find Full Text PDFprotein kinase inhibitors as Targeted therapy for glioblastoma: A meta-analysis of randomized controlled clinical trials.
Pharmacol Res
December 2024
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.
View Article and Find Full Text PDFCD8 + T-Cell-Related Genes: Deciphering Their Role in the Pancreatic Adenocarcinoma TME and Their Effect on Prognosis.
Dig Dis Sci
November 2024
Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No. 59 Haier Road, Qingdao, 266000, Shandong, China.
Article Synopsis
- Immunotherapy and targeted therapies struggle to effectively treat pancreatic adenocarcinoma (PAAD) due to its unique tumor microenvironment (TME), highlighting the importance of CD8+ T cells in this context.
- * Researchers utilized gene coexpression network analysis and algorithms to assess PAAD data from The Cancer Genome Atlas, aiming to understand CD8+ T-cell infiltration and develop a risk score model for patient prognosis.
- * A validated risk model, based on five CD8-related genes, indicated that patients in a low-risk group had better survival outcomes, while also finding correlations between tumor mutation burden and immune function associated with the risk score.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!